-
2023-510320-71-00
4
2020-10-27
Squamous cell carcinoma of vulva/vagina
-
2024-516670-29-00
4
2020-09-15
Multiple Myeloma
-
2024-515343-39-00
4
2020-08-14
Malignant Peritoneal Mesothelioma
-
2023-507846-96-00
5
2020-06-19
Type 2 Diabetes Mellitus
-
2024-516407-16-00
5
2020-04-10
Patients admitted to the ICU proven or suspected infection as the main
-
2024-513984-22-00
4
2020-03-17
Patients with metastatic GIST
-
2023-508293-28-00
5
2020-02-20
Dermatomyositis
-
2024-511427-34-00
5
2020-02-20
idiopathic pulmonary fibrosis
-
2023-506248-18-00
7
2020-01-07
MET-altered non-small cell lung cancer (NSCLC)
-
2022-502886-71-00
5
2019-11-20
Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
-
2024-514873-22-00
5
2019-10-16
Unresectable locally advanced and/or metastatic soft-tissue sarcoma
-
2024-513977-31-00
4
2019-07-17
Untreated squamous cell carcinoma of the head and neck
-
2024-511885-35-00
5
2019-07-03
macular telangiectasia type 1
-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2022-500797-34-00
4
2018-12-17
Treatment of participants with positive cancer for HRRm or HRD.
-
2023-510426-33-00
5
2018-09-27
Moderately to Severely Active Crohn's Disease
-
2023-508083-30-00
4
2018-07-19
Non-small cell lung cancer (NSCLC)
-
2023-504038-23-00
9
2018-05-10
Metastatic non-small cell lung cancer (NSCLC)
-
2024-514586-20-01
5
2018-05-02
Non small cell lung cancer
-
2024-516783-29-00
6
2018-04-16
Severe allergic and eosinophilic asthma
-
2024-516904-40-00
5
2018-03-27
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
-
2024-515000-39-00
9
2017-01-17
Recurrent glioblastoma.
-
2022-500400-22-00
5
2016-06-23
Hodgkin lymphoma
-
2023-509360-24-00
5
2016-06-16
Subjects with resected adenocarcinoma or squamous cell carcinoma esoph